Phase 3 observational extension study of Lorecivivint, intra-articular CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways. Safety and tolerability. Efficacy at 6 and 12 month, but at 18month it disappeared @RheumNow #ACR21 abst#0729 https://t.co/9ycbVGKkmy